Feb 16 2010
Medical device pioneer Stentys announced today that the complete ‘OPEN-I’
clinical study was presented by Stefan Verheye, M.D., Ph.D.,
at the Joint Interventional Meeting (“JIM”) 2010 in Rome,
demonstrating superior results in 60 patients (27 Stentys
drug-eluting stents and 33 Stentys bare-metal stents) who were
followed–up angiographically after six months.
“We are actively pursuing our
clinical program, particularly in the treatment of Acute Myocardial
Infarction, to also prove the superiority of the Stentys technology in
this additional group of patients.”
“These clinical results suggest very promising benefits for patients,”
said Stefan Verheye, M.D., Ph.D., Department of Cardiology,
Middelheim Hospital, Antwerp, Belgium. “We had already demonstrated that
the self-expanding and disconnectable Stentys platform
ensured optimal wall apposition and easy access to side branches. We can
now confirm that the addition of a drug coating eliminates the need for
reintervention.”
“These data fortify our conviction of the indisputable superiority of
Stentys self-expanding and drug-eluting stents over balloon-expandable
DES for the treatment of complex cases,” added Gonzague Issenmann,
CEO and co-founder of Stentys. “We are actively pursuing our
clinical program, particularly in the treatment of Acute Myocardial
Infarction, to also prove the superiority of the Stentys technology in
this additional group of patients.”